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nicely correlated with thickening of the synovial lining layer comprising
activated macrophages. When collagenase-induced-osteoarthritis was
elicited in S100A9−/− mice, signiﬁcantly lower synovial activation was
observed when compared to WT mice. Synovial activation was 62% lower
at day 42. Cartilage destruction was signiﬁcantly lower in all surfaces
and ranged from a 45% reduction in the lateral tibia to 73% reduction in
the medial femur. When primary mouse chondrocytes were stimulated
with S100A8 or S100A9, a strong upregulation of particularly MMP-3
mRNA level was found indicating a direct role of S100A8/A9 in cartilage
destruction.
Conclusions: Alarmins S100A8/S100A9 are expressed by phagocytes in
biopsies of early OA patients. S100A8/A9 play a crucial role in synovial
activation and cartilage destruction in an osteoarthritis model that shows
clear synovial involvement. S100A8/A9 expression in the synovium
causes pathology probably by stimulating MMP-mediated damage in
the cartilage matrix.
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Purpose: Oncostatin M (OSM) is a multipotent cytokine that is expressed
in synovium from rheumatoid arthritis (RA) and osteoarthritis (OA)
patients. OSM alone, or in concert with pro-inﬂammatory cytokines
such as IL-1 or TNF, can stimulate synovial ﬁbroblasts (SFs) to express
genes that promote inﬂammation and joint destruction in arthritis. This
study determined the acute effects of OSM, IL-1, and TNF and their
combination on expression of IL-6 and RANKL in SFs.
Methods: SFs were isolated from non-arthritic mice deﬁcient in OSM
receptor expression (OSMR−/−) and strain-matched wildtype control
mice (OSMR+/+). SFs were stimulated with mouse OSM (2ng/mL), mouse
IL-1 (10ng/mL) or mouse TNF (7.5 ng/mL) and their combination for 1,
6 and 24 hrs. Gene expression was assessed by quantitative RT-PCR
analyses. Flow cytometry and immunohistochemistry were performed
to identify protein expression.
Results: In OSMR+/+ SFs, OSM and IL-1 increased IL-6 mRNA expression
by 80 fold at 6 hrs, with OSM further increasing expression at 24 hrs
(135 fold vs. 40-fold, IL-1). TNF treatment resulted in a small transient
increase in IL-6 mRNA expression which peaked at 1 hr (9 fold) and
returned to baseline by 24 hrs. Profound synergistic upregulation of IL-6
mRNA expression was observed when suboptimal doses of OSM and
IL-1 were combined (>1000-fold at 6 and 24 hrs). Combining TNF and
OSM enhanced IL-6 mRNA expression compared to each cytokine alone
at 1 hr (232-fold) but this combination had no additional effect at 6
and 24 hrs compared to OSM alone. OSM, IL-1 and TNF all increased
RANKL mRNA expression at 6 hrs (9 Fold, OSM; 4 Fold, TNF and IL1),
with the effects of TNF and IL-1 returning to baseline by 24 hrs. OSM
treatment, however, further increased RANKL mRNA expression at 24
hrs (20 fold). Combining suboptimal doses of OSM and IL-1 signiﬁcantly
enhanced RANKL expression at 24 hrs (100-fold) but this interaction
was not synergistic. Combining OSM and TNF had no additional effect
on RANKL expression compared to OSM alone. Importantly, OSMR−/− SFs
showed no induction of IL-6 or RANKL mRNA expression in response to
OSM treatment, but did respond to IL-1 and TNF treatment in a similar
manner to the OSMR+/+ SFs. In OSMR+/+ SFs, OSM stimulated mRNA
expression of its co-receptors (OSMR, 6-fold at 6 and 24 hrs, and gp130,
3-fold at 24 hrs). Furthermore, OSM increased IL-1 receptor mRNA and
protein expression at 24 hrs. IL-1 did not regulate its own receptor, but
induced a 3-fold increase in OSMR mRNA expression at 6 and 24 hrs.
OSM had no effect on TNF receptor expression. Finally, immunostaining
demonstrated protein expression of OSM and its co-receptors in the
synovium in normal mouse knee joints; expression was increased in
antigen-induced arthritis and was evident in the mouse surgical model
of osteoarthritis (destabilization of the medial meniscus).
Conclusions: Together our data show that OSM, acting alone or in
synergy with IL-1 or together with TNF, is a potent regulator of IL-6
and RANKL expression in SFs. These effects of OSM are dependent
on OSMR expression. The ability of OSM and IL-1 to cross-regulate
expression of their respective receptors contributes to the synergistic
effect of these cytokines in SFs. This study identiﬁes a signiﬁcant role
for OSM, acting through OSMR, in mediating inﬂammation and bone
destruction in arthritic joints.
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Purpose: There has been a paucity of lifecourse research on the risk
of osteoarthritis (OA). We performed a lifecourse analysis of potential
risk factors for hip OA (deﬁned by osteophytes and femoral head score
on ultrasound) acting at different stages of life, among members of the
Newcastle Thousand Families birth cohort.
Methods: Potential risk factors for hip OA (including birth weight and
breast feeding data) have been collected prospectively in this birth cohort
and an a priori conceptual framework was developed. Participants from
the cohort aged 63 years (born in May-June 1947), had both hips scanned
by a trained musculoskeletal sonographer. Ultrasound protocols were
derived from EULAR guidelines. Hip OA was considered to be present if
an osteophyte or femoral head abnormality was identiﬁed. These data
were analysed in relation to a range of factors from across the lifecourse
using logistic regression models.
Results: Prevalence of hip OA was 26%, 30% and 40% for right, left
and “any” hip, respectively; among 311 participants. There was no
signiﬁcant difference of hip OA prevalence between males and females
(p = 0.8). While birth weight, exclusive breast feeding at birth, adverse
life events in childhood and height at age 50 showed signiﬁcant
univariate associations with hip OA in men, it was only adverse life
events in childhood (OR 3.56 one event vs no event; 95% CI 1.16, 10.9;
p = 0.03) and height at age 50 (OR 0.87 per cm; CI 0.79, 0.96; p = 0.004)
that showed signiﬁcant associations in the adjusted model for males.
Exclusive breast feeding (OR 0.77 per month; CI 0.58, 1.01; p = 0.06)
showed borderline signiﬁcance in the adjusted model for males. In
contrast, higher education level (OR 0.10 graduate vs not completed
school; CI 0.01, 0.85; p = 0.03) and dietary intake of vitamin D at age 50
(OR 0.75 per microgram per day; CI 0.59, 0.95; p = 0.02) were found to
be protective against hip OA in women, while an increased body fat
percentage at age 50 conferred a slightly higher risk of hip OA (OR 1.05;
CI 1.0, 1.1; p = 0.03) in the adjusted model for women.
Conclusions: This is the ﬁrst study to perform a lifecourse analysis of hip
OA risk using prospectively collected data. Tall men with no adverse life
events in childhood were at a signiﬁcantly decreased risk of hip OA in
this study. Increased height might be a function of genetic status, better
nutrition (at birth and in childhood), decreased infections and/or better
socio-economic status; the factors for the association of hip OA with
height require further study to explain this relationship. Adverse life
events in childhood might inﬂuence their effect on subsequent hip OA
through psychological and social pathways, which was beyond the scope
of this study. The borderline signiﬁcance of exclusive breast feeding in
men is an interesting ﬁnding. While breast feeding is known to decrease
risk of adult obesity and therefore of hip OA, this study suggests that
exclusive breast feeding might be an independent predictor of hip OA in
men. The mechanism for this could be reduced burden of infection and
inﬂammation through the lifecourse – a testable hypothesis.
The protective effect of higher education in women from subsequent hip
OA is a novel ﬁnding. We hypothesise that this might reﬂect adoption of
healthier lifestyles among educated women or might even be a function
of their improved utilisation and uptake of healthcare services. The
protective effect of dietary intake of vitamin D in women is in line with
results from the Study of Osteoporotic fractures (NE Lane et al, Arthritis
Rheum; 1999)which showed a similar protective effect of dietary Vitamin
D intake on incident hip OA in women. This protective effect of vitamin
D intake was independent of its effect on BMD at age 50. The ﬁndings of
this study have potential implications to public health policy especially
with regard to dietary vitamin D intake in women.
